HSV-2感染的发病机制及诊疗进展  

Progress of pathogenesis,diagnosis,and treatment on HSV-2 infection

作　　者：张昊 刘涛[2] 邱源旺 陈仁芳 ZHANG Hao;LIU Tao;QIU Yuanwang;CHEN Renfang(The Fifth People's Hospital of Wuxi,Wuxi 214000,China;School of Integrated Traditional Chinese and Western Medicine,Nanjing University of Traditional Chinese Medicine,Nanjing 210000)

机构地区：[1]无锡市第五人民医院,江苏无锡214000 [2]南京中医药大学中西医结合学院,南京210000

出　　处：《中国艾滋病性病》2021年第11期1322-1325,共4页Chinese Journal of Aids & STD

基　　金：南京医科大学科技发展基金一般项目(NMUB2018275)。

摘　　要：2型单纯疱疹病毒(HSV-2)感染机体可造成反复发作的终生感染。HSV-2首先感染黏膜上皮细胞,在感染机体的不同阶段激活不同的免疫反应。HSV-2产生免疫逃逸的关键环节在于HSV-2作用于多种DNA受体通路抑制了I型干扰素的表达。HSV-2与HIV-1在感染过程中互相促进,创造了有利于彼此复制的微环境。传统的HSV-2感染诊断方法可能会忽略急性感染。解旋酶抑制剂是一种有前途的治疗HSV-2感染的药物。目前已有进入临床试验的预防性疫苗和治疗性疫苗,后者表现出较好的前景。Herpes simplex virus type 2(HSV-2)can cause recurrent life-long infections in the body.HSV-2 first infects mucosal epithelial cells and activates different immune responses to varying stages of the disease.The critical link in HSV-2’s immune escape is that HSV-2 acts on multiple DNA receptor pathways to inhibit the expression of type I interferon.HSV-2 and HIV-1 create a microenvironment conducive to promote each other’s replication during the infection process.Traditional HSV-2 infection diagnosis methods may ignore acute infections.Helicase inhibitor is a promising drug for the treatment of HSV-2 infection.Preventive vaccines and therapeutic vaccines have entered clinical trials,and the latter shows good prospects.

关 键 词：2型单纯疱疹病毒 生殖器疱疹 艾滋病病毒 

分 类 号：R759[医药卫生—皮肤病学与性病学] R373.9[医药卫生—临床医学]